Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Investing.com -- InMed Pharmaceuticals Inc (NASDAQ:INM) stock doubled on Tuesday following the announcement of promising preclinical data for its Alzheimer’s disease drug candidate INM-901.
The pharmaceutical company revealed that INM-901 significantly reduced inflammation in ex vivo models of neuroinflammation, supporting its potential as a therapeutic candidate for Alzheimer’s disease. The study demonstrated that the drug reduced pro-inflammatory cytokines and may directly impact neuroinflammation independent of amyloid beta or tau aggregation.
Key findings showed INM-901 significantly reduced levels of NLRP3 and IL-1β, two inflammasome markers implicated in Alzheimer’s disease pathogenesis. The treatment resulted in a dose-dependent and statistically significant reduction in several pro-inflammatory markers, including IL-6, IL-1β, KC/Gro, and IL-2.
"NLRP3-driven inflammation is recognized as a key contributor to neurodegenerative disease progression," said Dr. Eric Hsu, SVP of Preclinical Research & Development at InMed. "The data derived from this LPS-induced inflammation study further support our previous findings in the amyloid beta animal model following INM-901 treatment."
The company plans to advance INM-901 through additional preclinical studies, with IND-enabling studies to follow. InMed describes INM-901 as a proprietary small molecule drug candidate with potentially multiple mechanisms of action, including reduced neuroinflammation and improved neurite growth and neuronal function.
The drug can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection, potentially offering advantages over currently approved products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.